 |
市场调查报告书
商品编码
1621833
免疫调节剂市场机会、成长动力、产业趋势分析与预测 2024 - 2032Immunomodulators Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
||||||
2023 年全球免疫调节剂市场价值为 2,177 亿美元，预计 2024 年至 2032 年复合年增长率为 6.7%。自体免疫疾病、癌症和慢性感染等疾病。有几个因素推动了市场的成长，包括自体免疫疾病和发炎性疾病的日益普及、生物技术和药物研究的不断进步以及对免疫调节疗法的认识不断增强。医疗保健支出的增加和对有效治疗的需求不断增长也促进了市场的扩张。此外，新冠肺炎后併发症的激增进一步加速了对免疫调节剂的需求，因为这些疗法被用于管理长期呼吸问题和其他健康挑战。
市场分为两大产品类型：免疫抑制剂和免疫增强剂。免疫抑制剂在 2023 年占据最大收入份额，为 1,365 亿美元，预计在预测期内将稳定成长。随着全球器官移植率持续上升，对器官移植药物的需求增加推动了这一成长。免疫抑制剂在预防器官排斥和确保移植成功方面发挥着至关重要的作用。
按应用细分时，免疫调节剂市场包括肿瘤学、自体免疫疾病、传染病和其他应用。 2023 年，肿瘤学领域引领市场，价值 854 亿美元。免疫调节剂越来越多地用于癌症治疗，以帮助增强免疫系统瞄准和破坏癌细胞的能力。这些疗法包括免疫检查点抑制剂、细胞激素和癌症疫苗，由于它们能够改变免疫环境以更有效地对抗肿瘤，因此在现代肿瘤学中变得至关重要。
| 市场范围 | |
|---|---|
| 开始年份 | 2023年 |
| 预测年份 | 2024-2032 |
| 起始值 | 2177 亿美元 |
| 预测值 | 3,887 亿美元 |
| 复合年增长率 | 6.7% |
预计北美将主导免疫调节剂市场，预计到 2032 年将达到 1,783 亿美元。患有多种慢性病的人数不断增加，显着增加了该地区对免疫调节治疗的需求，推动了市场成长和创新。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 自体免疫疾病和癌症的盛行率不断增加
- 生物技术的进步
- 在慢性病管理中越来越多地采用生物製剂和生物相似药
- 产业陷阱与挑战
- 免疫调节疗法相关的高成本
- 潜在的副作用和长期的安全性问题
- 成长动力
- 成长潜力分析
- 监管环境
- 技术景观
- 未来市场趋势
- 波特的分析
- PESTEL分析
第 4 章：竞争格局
- 介绍
- 公司市占率分析
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 战略仪表板
第 5 章：市场估计与预测：按产品类型，2021 - 2032 年
- 主要趋势
- 免疫抑制剂
- 免疫增强剂
第 6 章：市场估计与预测：按应用分类，2021 - 2032
- 主要趋势
- 肿瘤学
- 自体免疫疾病
- 传染病
- 其他应用
第 7 章：市场估计与预测：按配销通路，2021 - 2032 年
- 主要趋势
- 医院药房
- 零售药房
- 网路药房
- 其他最终用户
第 8 章：市场估计与预测：按地区，2021 - 2032
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
第 9 章：公司简介
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca PLC
- Biogen Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Limited
- UCB SA
The Global Immunomodulators Market was valued at USD 217.7 billion in 2023 and is projected to grow at a CAGR of 6.7% from 2024 to 2032. Immunomodulators, which can either enhance (immunostimulants) or suppress (immunosuppressants) immune system activity, are essential for treating conditions such as autoimmune diseases, cancer, and chronic infections. Several factors drive the market growth, including the increasing prevalence of autoimmune and inflammatory diseases, ongoing advancements in biotechnology and pharmaceutical research, and a growing awareness of immunomodulatory therapies. Rising healthcare expenditures and the growing need for effective treatments also contribute to the market expansion. Additionally, the surge in post-COVID complications has further accelerated the demand for immunomodulators, as these therapies are being used to manage long-term respiratory issues and other health challenges.
The market is divided into two major product types: immunosuppressants and immunostimulants. Immunosuppressants, which accounted for the largest revenue share of USD 136.5 billion in 2023, are projected to grow steadily over the forecast period. This growth is driven by an increased demand for organ transplant medications as the global rate of organ transplants continues to rise. Immunosuppressants play a vital role in preventing organ rejection and ensuring transplant success.
When segmented by application, the immunomodulators market includes oncology, autoimmune diseases, infectious diseases, and other applications. The oncology segment led the market in 2023, valued at USD 85.4 billion. Immunomodulators are increasingly being used in cancer treatment to help strengthen the immune system's ability to target and destroy cancer cells. These therapies, which include immune checkpoint inhibitors, cytokines, and cancer vaccines, are becoming crucial in modern oncology for their ability to modify the immune environment to fight tumors more effectively.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $217.7 Billion |
| Forecast Value | $388.7 Billion |
| CAGR | 6.7% |
North America is expected to dominate the immunomodulators market, with projections reaching USD 178.3 billion by 2032. The U.S. generated USD 91.2 billion in 2023, primarily due to the high prevalence of chronic diseases. The growing number of individuals living with multiple chronic conditions is significantly increasing the demand for immunomodulatory treatments in the region, driving market growth and innovation.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360°-degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of autoimmune diseases and cancer
- 3.2.1.2 Advancements in biotechnology
- 3.2.1.3 Growing adoption of biologics and biosimilars in chronic disease management
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High costs associated with immunomodulatory therapies
- 3.2.2.2 Potential side effects and long-term safety concerns
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Immunosuppressants
- 5.3 Immunostimulants
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Oncology
- 6.3 Autoimmune diseases
- 6.4 Infectious diseases
- 6.5 Other applications
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacy
- 7.3 Retail pharmacy
- 7.4 Online pharmacy
- 7.5 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 AbbVie Inc.
- 9.2 Amgen Inc.
- 9.3 AstraZeneca PLC
- 9.4 Biogen Inc.
- 9.5 Bristol-Myers Squibb Company
- 9.6 Eli Lilly and Company
- 9.7 F. Hoffmann-La Roche AG
- 9.8 Gilead Sciences, Inc.
- 9.9 Johnson & Johnson
- 9.10 Merck & Co., Inc.
- 9.11 Novartis AG
- 9.12 Pfizer Inc.
- 9.13 Sanofi
- 9.14 Teva Pharmaceutical Industries Limited
- 9.15 UCB S.A.
